Allakos Inc   (ALLK)
Other Ticker:  
Price: $2.4000 $-0.10 -4.000%
Day's High: $2.5999 Week Perf: 10.6 %
Day's Low: $ 2.39 30 Day Perf: -16.96 %
Volume (M): 949 52 Wk High: $ 8.73
Volume (M$): $ 2,277 52 Wk Avg: $5.40
Open: $2.50 52 Wk Low: $2.02

 Market Capitalization (Millions $) 208
 Shares Outstanding (Millions) 87
 Employees 149
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -151
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 3

Allakos Inc
Allakos Inc. is a biopharmaceutical company based in California that specializes in the development of therapeutic antibodies for the treatment of various immune-mediated diseases. The company was founded in 2012 by Nessa Carion and Dr. Robert Alexander, and went public in 2018 (NASDAQ: ALLK).

Allakos has a unique focus on eosinophilic and mast cell-related diseases, which are conditions that result from the dysfunction of certain types of immune cells. These diseases can be chronic and debilitating, affecting multiple organ systems and leading to a host of complications.

Allakos has several drug candidates in its pipeline, with its lead product, AK002, being tested clinically for several indications, including eosinophilic gastritis and urticaria, chronic rhinosinusitis with nasal polyps, and indolent systemic mastocytosis. AK002 is an antibody that targets the cell surface receptor Siglec-8, which is expressed on eosinophils and mast cells. By binding to Siglec-8, AK002 is thought to reduce the activation and proliferation of these cells, thereby reducing inflammation and symptoms associated with the target diseases.

In addition to AK002, Allakos is also developing two other drug candidates: AK001, which targets a different receptor on mast cells, and AK003, which targets a cytokine called IL-33 that is involved in the activation of mast cells and other immune cells.

Allakos has a robust research program, with a strong focus on identifying new drug targets and developing novel therapies for unmet medical needs. The company has collaborations with academic and industry partners, including the National Institutes of Health, to leverage their expertise and resources.

Overall, Allakos is a dynamic and growing biopharmaceutical company that is making strides in developing new treatments for immune-mediated diseases. Its innovative approach and promising drug candidates have garnered attention from investors, clinicians, and patients alike.

   Company Address: 825 Industrial Road San Carlos 94070 CA
   Company Phone Number: 597-5002   Stock Exchange / Ticker: NASDAQ ALLK
   ALLK is expected to report next financial results on November 06, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Immuron Limited

Immuron Limited reports decreased revenue and widened net loss in Q4 2023

In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.

Procyon Corporation

Observing the fourth quarter of 2023 numbers, Procyon Corporation reveals concerning revenue decline

Procyon Corporation recently released their financial results for the fourth quarter of the 2023 earnings season. While the company reported unaltered earnings per share (EPS), a decline in revenue and other key indicators raises concerns about the company's future performance. This article aims to interpret the financial results and discuss their potential impact on Procyon Corporation going forward.
1. Earnings per Share (EPS) and Revenue Performance:
Procyon Corporation maintained an EPS of $0.00 in the fourth quarter, suggesting stability in their profitability. However, the company experienced a modest revenue decline of -0.589% year-on-year, amounting to $1.20 million. This decline sets Procyon apart from the rest of the Major Pharmaceutical Preparations industry, which recorded a revenue improvement during the same period.

Innovation Pharmaceuticals Inc

Revitalizing Growth: Innovation Pharmaceuticals Inc's Revenue Stagnant, But Positive Signs Emerge

Innovation Pharmaceuticals Inc, a pharmaceutical company, recently announced its financial results for the fiscal year ending June 30, 2023. During this period, the company achieved a break-even point of $0.00 per share, which was the same as the previous year and the previous quarter.
However, the company did not generate any revenue during this quarter, remaining at $0.00 million, the same as the previous year and quarter. This indicates that there was no growth in the company's revenue during this period.
Additionally, Innovation Pharmaceuticals Inc reported a net shortfall of $-0.681 million for the fiscal year ending June 30, 2023. This is a significant improvement compared to the deficit of $-1.626 million reported in the same quarter a year ago. Although still in a shortfall, the company has managed to reduce its losses, which may indicate positive efforts in managing their expenses.

Palatin Technologies Inc

Palatin Technologies Inc Defies the Odds with Explosive Revenue Growth in Q4 2023, While Major Pharmaceutical Preparations Companies Struggle to Turn Profitable

Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.

Ibio Inc

Ibio Inc's Fourth Quarter Earnings Show Alarming Surge in Losses and Share Value Decline

In the aftermath of Ibio Inc's recently released fourth-quarter earnings report, the company appears to be grappling with mounting losses and a steep decline in its share value. The financial results for the quarter ended in 2023 revealed a concerning trend of escalating losses for the biotechnology firm.
Earnings Overview:
During the fourth quarter of the 2023 earnings season, Ibio Inc reported a significant increase in its loss per share compared to the same period in the prior year. The loss per share surged from $-0.10 a year ago to $-0.97, representing a substantial deterioration. Additionally, the company witnessed a sequential increase in losses, reaching $-0.55 per share from the previous financial reporting period.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com